Randomized Phase II Study with Cetuximab in Combination with 5-FU and Cisplatin or Carboplatin vs. Cetuximab in Combination with Paclitaxel and Carboplatin for Treatment of Patients with Relapsed or Metastatic Squamous Cell Carcinoma of the Head and Neck (CETMET Trial).

Cancers (Basel) · 2020 · PMC7693024 · PMID 33114379

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

All other endpoints had a positive trend towards favoring the experimental arm, though no statistically significant differences were observed, except for the OR rate which was superior in the experimental arm, due to a proportionally larger number of patients with CR.

also in 11,005 other papers

a strong trendno p-value reported

PFS HR for arm B was 0.65 (95% CI: 0.41–1.03), therefore not significantly worse than arm A and with a strong trend to superiority towards arm A.

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.